BioTesserae Conducts Milestone First in Dog Studies with Proprietary PD-1 Single Domain Antibody
BioTesserae Inc. (BTC), a biotechnology company focused on innovative veterinary therapeutics, in collaboration with Sunflower Therapeutics PBC, a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, today announced that BTC-001 was well tolerated in healthy dogs following a single ascending dose study. BTC-001 is a single domain antibody (SdA) that recognizes the immune checkpoint inhibitor PD-1 and is part of BioTesserae’s growing portfolio of biologic drugs for the treatment of cancer in companion animals.
